Patrick A Ott Selected Research

Immune Checkpoint Inhibitors

1/2022	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
1/2022	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
10/2021	Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
8/2021	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
5/2021	Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.
1/2021	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
1/2021	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
1/2021	CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
1/2021	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.
1/2021	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick A Ott Research Topics

Disease

78	Neoplasms (Cancer) 11/2022 - 01/2010
77	Melanoma (Melanoma, Malignant) 01/2022 - 01/2009
13	Disease Progression 01/2022 - 05/2015
10	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2011
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 03/2013
7	Brain Neoplasms (Brain Tumor) 10/2021 - 01/2009
7	Colitis 01/2021 - 11/2016
5	Pneumonia (Pneumonitis) 08/2021 - 07/2016
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2020 - 02/2015
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 06/2017
4	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2020
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2005 - 09/2002
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 07/2016
3	Uveal melanoma 12/2018 - 10/2013
3	Exanthema (Rash) 01/2017 - 01/2009
3	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2016
2	Lung Neoplasms (Lung Cancer) 01/2022 - 12/2016
2	COVID-19 01/2022 - 05/2021
2	Inflammation (Inflammations) 01/2019 - 03/2013
2	Carcinoma (Carcinomatosis) 01/2019 - 11/2016
2	Endometrial Neoplasms (Endometrial Cancer) 12/2017 - 08/2017
2	Hypothyroidism 12/2017 - 01/2017
2	Hypophysitis 11/2016 - 02/2015
2	Fatigue 11/2016 - 01/2009
2	Renal Insufficiency (Renal Failure) 07/2016 - 01/2013
2	Testicular Neoplasms (Testicular Cancer) 03/2015 - 06/2013
2	Infections 03/2013 - 02/2004
2	Thrombocytopenia (Thrombopenia) 01/2013 - 01/2009
2	Neutropenia 01/2013 - 01/2009
2	Chronic Disease (Chronic Diseases) 02/2004 - 09/2002
1	Triple Negative Breast Neoplasms 01/2022
1	Dermatitis 08/2021
1	Dyspnea (Shortness of Breath) 01/2021
1	Residual Neoplasm 01/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020

Drug/Important Bio-Agent (IBA)

49	Immune Checkpoint InhibitorsIBA 01/2022 - 06/2013
25	IpilimumabIBA 10/2021 - 06/2013
21	pembrolizumabIBA 01/2022 - 02/2015
16	VaccinesIBA 01/2022 - 06/2014
14	Monoclonal AntibodiesIBA 11/2021 - 03/2013
14	NivolumabIBA 10/2021 - 02/2015
12	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 02/2013
9	B7-H1 AntigenIBA 11/2022 - 08/2017
9	AntigensIBA 01/2022 - 02/2004
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 02/2004
8	LigandsIBA 01/2020 - 03/2013
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2013
7	CytokinesIBA 11/2021 - 09/2002
6	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2021 - 02/2015
5	Peptides (Polypeptides)IBA 01/2021 - 02/2004
5	Cancer VaccinesIBA 11/2020 - 01/2018
5	AntibodiesIBA 01/2017 - 01/2014
4	EpitopesIBA 01/2021 - 07/2004
4	CTLA-4 AntigenIBA 01/2021 - 06/2013
4	Pharmaceutical PreparationsIBA 01/2016 - 01/2014
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 06/2014
3	CreatinineIBA 01/2019 - 01/2013
3	trametinibIBA 01/2016 - 02/2013
3	EnzymesIBA 01/2015 - 02/2004
3	VemurafenibIBA 07/2013 - 04/2013
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2021
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 01/2011
2	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2019
2	ProdrugsIBA 01/2021 - 01/2021
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2017
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 03/2013
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2021
2	Monatide (IMS 3015)IBA 01/2020 - 03/2015
2	Glycoproteins (Glycoprotein)IBA 01/2019 - 11/2014
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 11/2014
2	glembatumumab vedotinIBA 01/2019 - 11/2014
2	Interleukin-10 (Interleukin 10)IBA 11/2018 - 10/2016
2	AutoantigensIBA 01/2018 - 07/2004
2	Phosphotransferases (Kinase)IBA 01/2017 - 10/2013
2	PlatinumIBA 11/2016 - 07/2016
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 09/2015
2	dabrafenibIBA 01/2016 - 01/2014
2	Cytotoxins (Cytolysins)IBA 11/2014 - 01/2011
2	Mitogen-Activated Protein KinasesIBA 01/2014 - 04/2013
2	Dacarbazine (DIC)FDA LinkGeneric 01/2013 - 01/2009
1	Circulating Tumor DNAIBA 01/2022
1	atezolizumabIBA 01/2022
1	MEDI3617IBA 11/2021
1	Angiopoietin-2IBA 11/2021
1	Immunoglobulin G (IgG)IBA 11/2021
1	tremelimumabIBA 11/2021
1	Interleukin-17 (Interleukin 17)IBA 08/2021
1	CD40 Ligand (CD40L)IBA 08/2021
1	TroponinIBA 05/2021
1	Protein Subunit VaccinesIBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	poly ICLCIBA 01/2020

Therapy/Procedure

55	Therapeutics 01/2022 - 06/2009
28	Immunotherapy 01/2022 - 02/2013
13	Drug Therapy (Chemotherapy) 01/2022 - 01/2009
8	Radiotherapy 01/2021 - 07/2013
3	Aftercare (After-Treatment) 01/2021 - 01/2017
1	Lymph Node Excision (Lymph Node Dissection) 01/2021
1	Transplantation 01/2020